H. Jackson

发表

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

Mark Shackleton, Gerd Ritter, Simon Green, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma

G. McArthur, I. Davis, A. Haydon, 2015, Cancer Immunology, Immunotherapy.

Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients

L. Old, I. Davis, J. Cebon, 2006, Journal of immunotherapy.

Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.

P. Gibbs, J. Karbach, M. Shackleton, 2003, Cancer immunity.

Spontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjects

P. Gibbs, J. Trapani, I. Davis, 1998, Cancer Immunology, Immunotherapy.

Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant.

J. McCluskey, N. Mifsud, L. Old, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma

M. Gore, C. Fisher, P. Hersey, 2020, Journal for ImmunoTherapy of Cancer.

A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant.

Lisa M. Ebert, I. Davis, J. Cebon, 2017, Immunotherapy.

Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma

Lisa M. Ebert, G. McArthur, I. Davis, 2009, Clinical Cancer Research.

A Novel HLA-B18 Restricted CD8+ T Cell Epitope Is Efficiently Cross-Presented by Dendritic Cells from Soluble Tumor Antigen

N. Mifsud, I. Davis, J. Cebon, 2012, PloS one.

Melan-A–specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4

Lisa M. Ebert, I. Davis, J. Cebon, 2009, Clinical Cancer Research.

Combining MHC tetramer and intracellular cytokine staining for CD8(+) T cells to reveal antigenic epitopes naturally presented on tumor cells.

Lisa M. Ebert, Weisan Chen, P. Guillaume, 2009, Journal of immunological methods.

Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein.

J. Cebon, K. Itoh, N. Komatsu, 2013, Molecular immunology.

Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™

L. Old, I. Davis, J. Cebon, 2011, Cancer Immunology, Immunotherapy.

A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples.

L. Old, I. Davis, J. Cebon, 2004, Journal of immunological methods.

Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination.

M. Shackleton, I. Davis, J. Cebon, 2005, Cancer immunity.

The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.

M. Jefford, M. Shackleton, I. Davis, 2004, Cancer immunity.

A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.

Lisa M. Ebert, J. Rossjohn, A. Purcell, 2009, Cancer research.

Erratum: Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans (Proceedings of the National Academy of Sciences of the United States of America (July 20, 2004) 101, 29 (10697-10702))

A. Scott, Yao-Tseng Chen, G. McArthur, 2005 .

Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro

Winston A Hide, C. Gedye, O. Caballero, 2015, Stem Cell Reviews and Reports.

Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1

Lisa M. Ebert, J. Cebon, Weisan Chen, 2010, Expert review of vaccines.

Striking Immunodominance Hierarchy of Naturally Occurring CD8+ and CD4+ T Cell Responses to Tumor Antigen NY-ESO-11

N. Mifsud, L. Old, I. Davis, 2006, The Journal of Immunology.

Functional and Structural Characteristics of NY-ESO-1-related HLA A2-restricted Epitopes and the Design of a Novel Immunogenic Analogue*

T. Beddoe, J. McCluskey, J. Rossjohn, 2004, Journal of Biological Chemistry.

A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: Implications for cancer vaccine design (Cancer Research (2009) 69, (1046-54))

Lisa M. Ebert, J. Rossjohn, A. Purcell, 2009 .

Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro

C. Maher, Winston A Hide, C. Gedye, 2015, Stem Cell Reviews and Reports.